Variant allele frequency: a decision-making tool in precision oncology...a thread sciencedirect.com/science/articl…

Excellent review Trends in Cancer about use of variant allele frequency as a biomarker for precision oncology. Well worth reading G Curigliano MD PhD Luca Boscolo Bielo cell.com/trends/cancer/…

Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 - Annals of Oncology annalsofoncology.org/article/S0923-…

Hot off the press in NatureRevClinOncol ! Using examples from trials presented at #ASCO23 , in this educational piece, I highlight how we should think about crossover in cancer clinical trials. Such education also forms a core theme of what we do Common Sense Oncology.
In this piece, I argue…

📢 On EJC our comprehensive analysis of current phase I clinical trials, led by Dr Repetto. Many drugs may be affected by the 'me too' phenomenon and few are against novel targets. Pairing TCGA data revealed underserved histologies G Curigliano MD PhD Alexander Drilon MD ejcancer.com/article/S0959-…

🔥Happy to share our 🇮🇹 contribution on platinum and PARPi post-progression tx in pts with mBC and gBRCA-PV

Thank you to all coauthors!

G Curigliano MD PhD Dario Trapani Caterina Sposetti Luca Boscolo Bielo Antonio Marra Diletta Favero Luca rossanaberardi Matteo Lambertini, MD PhD Lucia Del Mastro

Just out in JAMA Internal Medicine, we highlight a mechanism to detect selection bias/confounding in observational studies by looking at Kaplan Meier curves.

If the curves separate implausibly early, the findings are too good to be true!

jamanetwork.com/journals/jamai…

Vinay Prasad MD MPH

🇨🇦🧙‍♂️ (🦍/🐒) So true! Direct correlations with no recognition of a threshold effect aka a min improvement to be demonstrated, will lead to declare success based on no-relevant improvements, especially in the tiny-gain spaces.

As the cost of oncological drugs continues to rise, pressuring healthcare systems, we are happy to share our pharmacoeconomic evaluation of novel drugs in the TNBC setting.
Thrilled to share this work with two giants in the field G Curigliano MD PhD Dario Trapani

tandfonline.com/doi/full/10.10…

Happy to share the results of the first three years of activity of our IEO's molecular tumor board. A multidisciplinary critical and rational assessment of clinical and molecular characteristics can make a difference for our patients.
G Curigliano MD PhD Edoardo Crimini MD #mRepetto